# Jrome Bertherat

## List of Publications by Year in Descending Order

**Source:** https://exaly.com/author-pdf/8402650/jerome-bertherat-publications-by-year.pdf
**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 125 papers | 9,157 citations | 54 h-index | 94 g-index |
| 136 ext. papers | 10,882 ext. citations | 7.3 avg, IF | 5.61 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 125 | First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.. *Journal of Clinical Oncology*, **2022**, 40, 1-1 | 2.2 | 1 |
| 124 | KDM1A inactivation causes hereditary food-dependent Cushing syndrome.. *Genetics in Medicine*, **2021**, | 8.1 | 2 |
| 123 | CRH-Receptor Molecular Imaging Reveals the Intimacy of Corticotroph Adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e1902-e1904 | 5.6 | |
| 122 | Choroidal imaging in patients with Cushing syndrome. *Acta Ophthalmologica*, **2021**, 99, 533-537 | 3.7 | 2 |
| 121 | Genomic classification of benign adrenocortical lesions. *Endocrine-Related Cancer*, **2021**, 28, 79-95 | 5.7 | 5 |
| 120 | Update on primary bilateral macronodular adrenal hyperplasia (PBMAH). *Endocrine*, **2021**, 71, 595-603 | 4 | 6 |
| 119 | What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. *Endocrine Pathology*, **2021**, 32, 102-133 | 4.2 | 6 |
| 118 | Adrenalectomy during pregnancy: A 15-year experience at a tertiary referral center. *Surgery*, **2020**, 168, 335-339 | 3.6 | 4 |
| 117 | Update of Genetic and Molecular Causes of Adrenocortical Hyperplasias Causing Cushing Syndrome. *Hormone and Metabolic Research*, **2020**, 52, 598-606 | 3.1 | 8 |
| 116 | Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma. *Endocrine Connections*, **2020**, 9, 705-714 | 3.5 | 6 |
| 115 | Cullin 3 targets the tumor suppressor gene ARMC5 for ubiquitination and degradation. *Endocrine-Related Cancer*, **2020**, 27, 221-230 | 5.7 | 7 |
| 114 | Mass spectrometry-based steroid profiling in primary bilateral macronodular adrenocortical hyperplasia. *Endocrine-Related Cancer*, **2020**, 27, 403-413 | 5.7 | 4 |
| 113 | ARMC5 variants in PRKAR1A-mutated patients modify cortisol levels and Cushing's syndrome. *Endocrine-Related Cancer*, **2020**, 27, 509-517 | 5.7 | 2 |
| 112 | PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A. *Endocrine-Related Cancer*, **2020**, 27, 647-656 | 5.7 | 4 |
| 111 | SUN-714 Phenotype of Patients Carrying the c.709(-7-2)del PRKAR1A Mutation in a Large Cohort of 41 Patients. *Journal of the Endocrine Society*, **2020**, 4, | 0.4 | 78 |
| 110 | Link between steroidogenesis, the cell cycle, and PKA in adrenocortical tumor cells. *Molecular and Cellular Endocrinology*, **2020**, 500, 110636 | 4.4 | 1 |
| 109 | Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 27 |

| | | | |
|---|---|---|---|
| 108 | Pangenomic Classification of Pituitary Neuroendocrine Tumors. *Cancer Cell*, **2020**, 37, 123-134.e5 | 24.3 | 73 |
| 107 | F-fluorocholine PET/CT in MEN1 Patients with Primary Hyperparathyroidism. *World Journal of Surgery*, **2020**, 44, 3761-3769 | 3.3 | 8 |
| 106 | The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes. *International Journal of Environmental Research and Public Health*, **2020**, 17, | 4.6 | 6 |
| 105 | Molecular Basis of Primary Aldosteronism and Adrenal Cushing Syndrome. *Journal of the Endocrine Society*, **2020**, 4, bvaa075 | 0.4 | 4 |
| 104 | Letter to the Editor from Berthon: "Cardiac Myxoma Caused by Fumarate Hydratase Gene Deletion in Patient With Cortisol-Secreting Adrenocortical Adenoma". *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105, | 5.6 | 1 |
| 103 | Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2985-2993 | 5.6 | 24 |
| 102 | Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 2367-2374 | 5.6 | 57 |
| 101 | Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. *Frontiers in Endocrinology*, **2019**, 10, 487 | 5.7 | 4 |
| 100 | Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. *JAMA Oncology*, **2019**, 5, 1440-1447 | 13.4 | 31 |
| 99 | Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2019**, 33, 101294 | 6.5 | 6 |
| 98 | Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. *European Journal of Endocrinology*, **2019**, 180, 311-320 | 6.5 | 10 |
| 97 | OR02-6 Mass Spectrometry-Based Steroid Profiling Inprimary Bilateral Macronodular Adrenocortical Hyperplasia. *Journal of the Endocrine Society*, **2019**, 3, | 0.4 | 78 |
| 96 | SUN-444 Efficacy and Safety of Dopamine Agonists in Psychiatric Patients Treated with Antipsychotics and Presenting a Macroprolactinoma. *Journal of the Endocrine Society*, **2019**, 3, | 0.4 | 78 |
| 95 | Diseases Predisposing to Adrenocortical Malignancy (Li-Fraumeni Syndrome, Beckwith-Wiedemann Syndrome, and Carney Complex). *Experientia Supplementum (2012)*, **2019**, 111, 149-169 | 2.2 | 7 |
| 94 | Surgical management of pancreatic neuroendocrine tumors: an introduction. *Expert Review of Anticancer Therapy*, **2019**, 19, 1089-1100 | 3.5 | 7 |
| 93 | MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors. *European Journal of Endocrinology*, **2018**, 178, R215-R230 | 6.5 | 38 |
| 92 | Genetics of tumors of the adrenal cortex. *Endocrine-Related Cancer*, **2018**, 25, R131-R152 | 5.7 | 40 |
| 91 | The role of ARMC5 in human cell cultures from nodules of primary macronodular adrenocortical hyperplasia (PMAH). *Molecular and Cellular Endocrinology*, **2018**, 460, 36-46 | 4.4 | 22 |

| | | | |
|---|---|---|---|
| 90 | Adrenalectomy for incidentaloma: lessons learned from a single-centre series of 274 patients. *ANZ Journal of Surgery*, **2018**, 88, 468-473 | 1 | 3 |
| 89 | Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation. *Modern Pathology*, **2018**, 31, 1708-1716 | 9.8 | 16 |
| 88 | Activating PRKACB somatic mutation in cortisol-producing adenomas. *JCI Insight*, **2018**, 3, | 9.9 | 27 |
| 87 | Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. *Endocrine Connections*, **2018**, 7, 1409-1414 | 3.5 | 3 |
| 86 | Somatic mutations are frequent events in corticotroph tumor progression causing Nelson'S tumor. *European Journal of Endocrinology*, **2018**, 178, 57-63 | 6.5 | 30 |
| 85 | Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. *Endocrine-Related Cancer*, **2018**, 25, L13-L17 | 5.7 | 17 |
| 84 | Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. *Journal of Pathology*, **2017**, 242, 10-15 | 9.4 | 89 |
| 83 | Dosage-dependent regulation of expression by steroidogenic factor-1 drives adrenocortical carcinoma cell invasion. *Science Signaling*, **2017**, 10, | 8.8 | 24 |
| 82 | PDE 2015: cAMP Signaling, Protein Kinase A (PKA) and Phosphodiesterases (PDEs): How Genetics Changed the Way We Look at One of the Most Studied Signaling Pathways. *Hormone and Metabolic Research*, **2017**, 49, 237-239 | 3.1 | 0 |
| 81 | Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. *Scientific Reports*, **2017**, 7, 49 | 4.9 | 15 |
| 80 | mutation in a Portuguese family with primary bilateral macronodular adrenal hyperplasia (PBMAH). *Endocrinology, Diabetes and Metabolism Case Reports*, **2017**, 2017, | 1.4 | 5 |
| 79 | Calling Chromosome Alterations, DNA Methylation Statuses, and Mutations in Tumors by Simple Targeted Next-Generation Sequencing: A Solution for Transferring Integrated Pangenomic Studies into Routine Practice?. *Journal of Molecular Diagnostics*, **2017**, 19, 776-787 | 5.1 | 6 |
| 78 | Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 3491-3498 | 5.6 | 24 |
| 77 | Analysis of ARMC5 expression in human tissues. *Molecular and Cellular Endocrinology*, **2017**, 441, 140-145 | 4.4 | 21 |
| 76 | Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. *Journal of the Endocrine Society*, **2017**, 1, 646-649 | 0.4 | 48 |
| 75 | Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing'S syndrome. *JCI Insight*, **2017**, 2, | 9.9 | 25 |
| 74 | Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3345-52 | 5.6 | 16 |
| 73 | Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 3526-38 | 5.6 | 46 |

| | | | |
|---|---|---|---|
| 72 | Role of ACTH in the Interactive/Paracrine Regulation of Adrenal Steroid Secretion in Physiological and Pathophysiological Conditions. *Frontiers in Endocrinology*, **2016**, 7, 98 | 5.7 | 18 |
| 71 | EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. *Human Molecular Genetics*, **2016**, 25, 2789-2800 | 5.6 | 29 |
| 70 | Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. *Cancer Cell*, **2016**, 29, 723-736 | 24.3 | 324 |
| 69 | Primary Aldosteronism and ARMC5 Variants. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E900-9 | 5.6 | 78 |
| 68 | The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia. *European Journal of Endocrinology*, **2015**, 173, 435-40 | 6.5 | 36 |
| 67 | The Great Imitator in Endocrinology: A Painful Hypophysitis Mimicking a Pituitary Tumor. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 2837-40 | 5.6 | 12 |
| 66 | The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E997-1004 | 5.6 | 118 |
| 65 | The 10 Hounsfield units unenhanced computed tomography attenuation threshold does not apply to cortisol secreting adrenocortical adenomas. *European Journal of Endocrinology*, **2015**, 173, 325-32 | 6.5 | 17 |
| 64 | Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. *Nature Communications*, **2015**, 6, 6044 | 17.4 | 120 |
| 63 | Genetics of primary bilateral macronodular adrenal hyperplasia: a model for early diagnosis of Cushing's syndrome?. *European Journal of Endocrinology*, **2015**, 173, M121-31 | 6.5 | 28 |
| 62 | SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). *Modern Pathology*, **2015**, 28, 807-21 | 9.8 | 142 |
| 61 | Cell-to-cell communication in bilateral macronodular adrenal hyperplasia causing hypercortisolism. *Frontiers in Endocrinology*, **2015**, 6, 34 | 5.7 | 6 |
| 60 | The genetics of adrenocortical tumors. *Endocrinology and Metabolism Clinics of North America*, **2015**, 44, 311-34 | 5.5 | 20 |
| 59 | ARMC5 Mutations in a Large Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional Consequences. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, E926-35 | 5.6 | 89 |
| 58 | Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 4604-11 | 5.6 | 11 |
| 57 | The 'omics' of adrenocortical tumours for personalized medicine. *Nature Reviews Endocrinology*, **2014**, 10, 215-28 | 15.2 | 38 |
| 56 | Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E1113-9 | 5.6 | 101 |
| 55 | mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). *Human Molecular Genetics*, **2014**, 23, 5418-28 | 5.6 | 32 |

| | | | |
|---|---|---|---|
| 54 | Integrated genomic characterization of adrenocortical carcinoma. *Nature Genetics*, **2014**, 46, 607-12 | 36.3 | 423 |
| 53 | Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. *New England Journal of Medicine*, **2014**, 370, 1019-28 | 59.2 | 284 |
| 52 | Hepato-pancreato-biliary lesions are present in both Carney complex and McCune Albright syndrome: comments on P. Salpea and C. Stratakis. *Molecular and Cellular Endocrinology*, **2014**, 382, 344-345 | 4.4 | 7 |
| 51 | Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. *Endocrine-Related Cancer*, **2014**, 21, 567-77 | 5.7 | 130 |
| 50 | IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma. *PLoS ONE*, **2014**, 9, e103744 | 3.7 | 32 |
| 49 | WNT/Ecatenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. *Human Molecular Genetics*, **2014**, 23, 889-905 | 5.6 | 130 |
| 48 | Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. *European Journal of Endocrinology*, **2014**, 170, 385-91 | 6.5 | 26 |
| 47 | Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study.. *Journal of Clinical Oncology*, **2014**, 32, 4106-4106 | 2.2 | |
| 46 | Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 4080-8 | 5.6 | 56 |
| 45 | Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. *New England Journal of Medicine*, **2013**, 369, 2115-25 | 59.2 | 141 |
| 44 | Identification of a CpG island methylator phenotype in adrenocortical carcinomas. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E174-84 | 5.6 | 82 |
| 43 | Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1109-21 | 5.6 | 29 |
| 42 | Carney complex. *Frontiers of Hormone Research*, **2013**, 41, 50-62 | 3.5 | 41 |
| 41 | ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. *New England Journal of Medicine*, **2013**, 369, 2105-14 | 59.2 | 239 |
| 40 | Wnt/Ecatenin signalling in adrenal physiology and tumour development. *Molecular and Cellular Endocrinology*, **2012**, 351, 87-95 | 4.4 | 100 |
| 39 | Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. *Clinical Endocrinology*, **2012**, 77, 195-9 | 3.4 | 54 |
| 38 | Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E2063-9 | 5.6 | 53 |
| 37 | Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approach. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E301-11 | 5.6 | 36 |

| | | | |
|---|---|---|---|
| 36 | Wnt/Ecatenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E419-26 | 5.6 | 95 |
| 35 | Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, E208-14 | 5.6 | 80 |
| 34 | Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 3775-84 | 5.6 | 293 |
| 33 | Ecatenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. *Clinical Cancer Research*, **2011**, 17, 328-36 | 12.9 | 110 |
| 32 | Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. *Clinical Cancer Research*, **2010**, 16, 5133-41 | 12.9 | 87 |
| 31 | Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical CushingSs syndrome. *European Journal of Endocrinology*, **2010**, 163, 129-38 | 6.5 | 63 |
| 30 | Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. *Human Molecular Genetics*, **2010**, 19, 1561-76 | 5.6 | 175 |
| 29 | Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. *Cancer Research*, **2010**, 70, 8276-81 | 10.1 | 113 |
| 28 | CushingSs syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. *PLoS Genetics*, **2010**, 6, e1000980 | 6 | 75 |
| 27 | High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, E161-71 | 5.6 | 156 |
| 26 | Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. *Human Mutation*, **2010**, 31, 369-79 | 4.7 | 131 |
| 25 | Mutations in regulatory subunit type 1A of cyclic adenosine 5Smonophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2085-91 | 5.6 | 311 |
| 24 | The paradoxical increase in cortisol secretion induced by dexamethasone in primary pigmented nodular adrenocortical disease involves a glucocorticoid receptor-mediated effect of dexamethasone on protein kinase A catalytic subunits. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 2406-13 | 5.6 | 65 |
| 23 | Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. *Journal of Clinical Oncology*, **2009**, 27, 1108-15 | 2.2 | 280 |
| 22 | CushingSs disease. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2009**, 23, 607-23 | 6.5 | 115 |
| 21 | A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. *European Journal of Human Genetics*, **2008**, 16, 1245-53 | 5.3 | 83 |
| 20 | Wnt/beta-catenin and 3$5Scyclic adenosine 5Smonophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 4135-40 | 5.6 | 116 |
| 19 | Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. *Clinical Cancer Research*, **2008**, 14, 4016-24 | 12.9 | 81 |

| | | | |
|---|---|---|---|
| 18 | Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. *Clinical Cancer Research*, **2007**, 13, 844-50 | 12.9 | 93 |
| 17 | Prognostic parameters of metastatic adrenocortical carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 148-54 | 5.6 | 168 |
| 16 | Adrenocortical cancer: pathophysiology and clinical management. *Endocrine-Related Cancer*, **2007**, 14, 13-28 | 5.7 | 182 |
| 15 | A PRKAR1A mutation associated with primary pigmented nodular adrenocortical disease in 12 kindreds. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 1943-9 | 5.6 | 96 |
| 14 | Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2650-5 | 5.6 | 294 |
| 13 | Mechanisms of disease: adrenocortical tumors--molecular advances and clinical perspectives. *Nature Clinical Practice Endocrinology and Metabolism*, **2006**, 2, 632-41 | | 27 |
| 12 | A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. *Nature Genetics*, **2006**, 38, 794-800 | 36.3 | 247 |
| 11 | PRKAR1A mutations in primary pigmented nodular adrenocortical disease. *Pituitary*, **2006**, 9, 211-9 | 4.3 | 40 |
| 10 | Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. *Cancer Research*, **2005**, 65, 7622-7 | 10.1 | 357 |
| 9 | Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. *European Journal of Endocrinology*, **2005**, 153, 477-87 | 6.5 | 133 |
| 8 | In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 1302-10 | 5.6 | 86 |
| 7 | Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 1819-29 | 5.6 | 204 |
| 6 | Overexpression of serotonin4 receptors in cisapride-responsive adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia causing Cushing's syndrome. *Journal of Clinical Endocrinology and Metabolism*, **2003**, 88, 248-54 | 5.6 | 64 |
| 5 | Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. *Cancer Research*, **2003**, 63, 5308-19 | 10.1 | 156 |
| 4 | The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1980-5 | 5.6 | 50 |
| 3 | Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 4324-9 | 5.6 | 142 |
| 2 | Adrenal incidentalomas. *Current Opinion in Oncology*, **2002**, 14, 58-63 | 4.2 | 42 |
| 1 | Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. *American Journal of Human Genetics*, **2002**, 71, 1433-42 | 11 | 156 |